Expertise in
2
conditions

Xielan L. Zhao

139 Mid RenMin Road, 
Changsha, CN 
Expertise in
2
conditions
139 Mid RenMin Road, 
Changsha, CN 

Overview

Xielan Zhao practices practicing medicine in Changsha, China.

Zhao is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Hemophilia A, Blood Clots, Leukemia, and Chronic Myelogenous Leukemia (CML).

They are actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 2 clinical trials.

Locations

139 Mid RenMin Road, Changsha, 410011, China
Other Locations
87 Xiangya Road, Changsha, 410008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
A Phase 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: LOXO-305
Study Phase: Phase 2
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
View 1 Less Clinical Trial

40 Total Publications

m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis.
m6A Modification of ATOX1 Inhibits Acute Myeloid Leukemia Progression by Promoting Cuproptosis.
Journal: Cancer research communications
Published: July 29, 2025

Frequently Asked Questions about Xielan L. Zhao

Is Xielan L. Zhao a top-rated expert for Hemophilia A?

MediFind is an objective health platform that identifies experts based on real-world data. Xielan L. Zhao is classified as an Advanced expert for Hemophilia A, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xielan L. Zhao participate in research or clinical trials?

Yes. Xielan L. Zhao has published 40 articles and abstracts on conditions like Hemophilia A. You can view a list of Xielan L. Zhao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhao's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile